Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Current Liabilities: 2013-2025

Historic Total Current Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $205.2 million.

  • Amphastar Pharmaceuticals' Total Current Liabilities rose 29.07% to $205.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.2 million, marking a year-over-year increase of 29.07%. This contributed to the annual value of $173.8 million for FY2024, which is 22.91% down from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Total Current Liabilities stood at $205.2 million, which was up 16.34% from $176.4 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Total Current Liabilities' 5-year high stood at $258.0 million during Q3 2023, with a 5-year trough of $94.9 million in Q4 2022.
  • For the 3-year period, Amphastar Pharmaceuticals' Total Current Liabilities averaged around $195.1 million, with its median value being $199.1 million (2025).
  • In the last 5 years, Amphastar Pharmaceuticals' Total Current Liabilities spiked by 152.43% in 2023 and then slumped by 45.49% in 2024.
  • Amphastar Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $103.8 million in 2021, then fell by 8.62% to $94.9 million in 2022, then spiked by 137.62% to $225.4 million in 2023, then decreased by 22.91% to $173.8 million in 2024, then climbed by 29.07% to $205.2 million in 2025.
  • Its last three reported values are $205.2 million in Q3 2025, $176.4 million for Q2 2025, and $199.1 million during Q1 2025.